| Name | Title | Contact Details |
|---|
US Post Acute Care is a Management Services Organization providing value-added service to clinical practice groups specializing in the care of patients in the post-acute setting. An organization with a national footprint, US Post Acute Care provides a full array of management services including billing, recruiting, training, compliance, analytics, and practice development. US Post Acute Care structures its services offering both to serve the needs as well as leverage the capabilities of its clinicians: the physicians and advanced practitioners dedicated to improving the quality of care for their patients. US Post Acute Care has designed and launched a proprietary clinical excellence program called SmartPAC™, a comprehensive clinical program for post-acute care designed to enable practitioners to improve patient outcomes with better quality care. Please
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
IPG works with top national and regional commercial payers, as well as various manufacturers in the cardiovascular, neurological and orthopedic spaces.
Robert Bosch Healthcare is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genetics Squared is a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence and proprietary point-of-care equipment for the evaluation and management of cardiovascular disease.